Early Follicular Supplementation of Ganirelix in IVF 2004
- Registration Number
- NCT00461422
- Lead Sponsor
- The Baruch Padeh Medical Center, Poriya
- Brief Summary
Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results
- Detailed Description
GnRH antagonist offers many advantages when used in IVF-ET treatment, however, it is suspected to yield lower pregnancy rate when compared with the long GnRH agonist protocol.
Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results.
Consecutive patients are prospectively enrolled and randomly assigned to the study and control groups. Patients with low ovarian reserve or with uterine distortion are excluded from the study. Both groups are treated with recombinant FSH and the flexible GnRH antagonist protocol. Women in the study group are also treated with additional GnRH antagonist 0.25 mg/day on day 1, 2 and 3 of the menstrual cycle.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 50
- infertility
- IVF candidate
- failure of previous IVF attempt
- low ovarian reserve
- untreated distortion of uterine cavity
- medical contraindication for IVF treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Ganirelix Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
- Primary Outcome Measures
Name Time Method pregnancy rates one cycle
- Secondary Outcome Measures
Name Time Method differences in hormonal levels one cycle differences in the basic treatment doses one cycle oocyte counts one cycle fertilization rate one cycle cleavage rate one cycle
Trial Locations
- Locations (1)
The Baruch Padeh medical center, Poriya
🇮🇱Tiberias, Israel